J&J Hid Risperdal’s Risks From Arkansas Doctors, Lawyer Says
This article is for subscribers only.
Johnson & Johnson officials hid the risks of the antipsychotic drug Risperdal to boost sales and should be held liable for misleading Arkansas doctors and patients, a lawyer said.
J&J’s Janssen unit made misleading claims about Risperdal’s effectiveness in a letter to more than 6,000 Arkansas doctors and downplayed its diabetes risks on warning labels, Fletch Trammell, one of the state’s lawyers, told a jury in Little Rock today. Arkansas is seeking more than $1.25 billion in penalties over the Risperdal marketing campaign.